LOOK AT THIS No revenue, still in clinical trials, no approved product, trading at $75.37 PPS.
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will host a conference call and slide presentation to discuss preliminary results of its Phase II study looking at the incidence and severity of diarrhea in patients with early-stage HER2-positive breast cancer treated with extended adjuvant neratinib monotherapy and prophylactic loperamide.
Food for thought for investors here.